What can we learn from the Food and Drug Administration’s (FDA’s) controversial approval of the first drug for Duchenne Muscular Dystrophy (DMD)? Everybody at the FDA agrees : “There were major flaws in the design and conduct of the clinical trials using
Read More...
Read the complete post at http://healthaffairs.org/blog/2016/10/25/the-fdas-controversial-duchenne-drug-approval-and-the-moral-impulse-to-rescue/
Posted
Oct 25 2016, 08:38 AM
by
Health Affairs BlogHealth Affairs Blog